WELENUF
(Asenapine Sublingual Tablets)

COMPOSITION
WELENUF 5
Each uncoated sublingual tablet contains:
Asenapine Maleate equivalent to
Asenapine………………… 5 mg
Colour……….Brilliant blue Lake

WELENUF 10
Each uncoated sublingual tablet contains:
Asenapine Maleate equivalent to
Asenapine……………….. 10 mg

DESCRIPTION
Asenapine is a psychotropic agent that is available for sublingual administration. Asenapine belongs to the class dibenzo-oxepino pyrroles. Asenapine is a white to off-white powder. The chemical designation is (3aRS,12bRS)-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1Hdibenzo[2,3:6,7]oxepino[4,5-c]pyrrole(2Z)-2-butenedioate (1:1). Its molecular formula is $C_{17}H_{16}ClNO·C_4H_4O_4$ and its molecular weight is 401.84 (free base: 285.8). The chemical structure is:

DOSAGE FORM
Sublingual Tablets

INDICATION
For acute treatment of Schizophrenia in adults only.

DOSE AND METHOD OF ADMINISTRATION

	Starting Dose	**Recommended Dose**	**Maximum Dose**
Schizophrenia-acute treatment in adults	5 mg sublingually twice daily	5 mg sublingually twice daily	10 mg sublingually twice daily
Schizophrenia maintenance treatment in adults	5 mg sublingually twice daily for one week	10 mg sublingually twice daily	10 mg sublingually twice daily

Dosage in special populations
In a reported study of subjects with hepatic impairment who were treated with a single dose of asenapine 5 mg, there were increases in asenapine exposures (compared to subjects with normal hepatic function), that correlated with the degree of hepatic impairment. While the results indicated that no dosage adjustments are required in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment, there was a 7-fold increase (on average) in asenapine concentrations in subjects with severe hepatic impairment (Child-Pugh C) compared to the concentrations of those in subjects with normal hepatic function. Therefore, asenapine is not recommended in patients with severe hepatic impairment. Dosage adjustments are not routinely required on the basis of age, gender, race, or renal impairment status.

Switching from Other Antipsychotics
There are no systematically collected data to specifically address switching patients with schizophrenia or bipolar mania from other antipsychotics to asenapine or concerning concomitant administration with other antipsychotics. While immediate discontinuation of the previous antipsychotic treatment may be acceptable for some patients with schizophrenia, more gradual discontinuation may be most appropriate for others. In all cases, the period of overlapping antipsychotic administration should be minimized.

Administration: Do not swallow tablet.
Asenapine sublingual tablets should be placed under the tongue and left to dissolve completely. Sublingual tablets should not be crushed, chewed, or swallowed. Eating and drinking should be avoided for 10 minutes after administration.

USE IN SPECIAL POPULATIONS
Pregnancy
Pregnancy Category C:
There are no adequate and well-controlled studies of asenapine in pregnant women.

In animal studies, asenapine increased post-implantation loss and decreased pup weight and survival at doses similar to or less than recommended clinical doses. In these studies there was no increase in the incidence of structural abnormalities caused by asenapine.

Asenapine was not teratogenic in reproduction studies in rats and rabbits at intravenous doses up to 1.5 mg/kg in rats and 0.44 mg/kg in rabbits. These doses are 0.7 and 0.4 times, respectively, the maximum recommended human dose (MRHD) of 10 mg twice daily given sublingually on a mg/m^2 basis. Plasma levels of asenapine were measured in the rabbit study, and the area under the curve (AUC) at the highest dose tested was 2 times that in humans receiving the MRHD.

In a study in which rats were treated from day 6 of gestation through day 21 postpartum with intravenous doses of asenapine of 0.3, 0.9, and 1.5 mg/kg/day (0.15, 0.4, and 0.7 times the MRHD of 10 mg twice daily given sublingually on a mg/m= basis), increases in post-implantation loss and early pup deaths were seen at all doses, and decreases in subsequent pup survival and weight gain were seen at the two higher doses. A cross-fostering study indicated that the decreases in pup survival were largely due to prenatal drug effects. Increases in post-

implantation loss and decreases in pup weight and survival were also seen when pregnant rats were dosed orally with asenapine.

Non-teratogenic Effects
Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization. Asenapine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Labor and Delivery
The effect of asenapine on labor and delivery in humans is unknown.

Nursing Mothers
Asenapine is excreted in milk of rats during lactation. It is not known whether asenapine or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when asenapine is administered to a nursing woman. It is recommended that women receiving asenapine should not breast feed.

Pediatric Use
Safety and effectiveness in pediatric patients have not been established.

Geriatric Use
Reported clinical studies of asenapine in the treatment of schizophrenia and bipolar mania did not include sufficient numbers of patients aged 65 and over to determine whether or not they respond differently than younger patients. Of the approximately 2250 patients in pre-marketing clinical studies of asenapine, 1.1% (25) were 65 years of age or over. Multiple factors that might increase the pharmacodynamic response to asenapine, causing poorer tolerance or orthostasis, could be present in elderly patients, and these patients should be monitored carefully.

In elderly patients with psychosis, asenapine exposure (AUC) was on average 40% higher compared to younger adult patients.

Elderly patients with dementia-related psychosis treated with asenapine are at an increased risk of death compared to placebo. Asenapine is not approved for the treatment of patients with dementia-related psychosis.

Renal Impairment
The exposure of asenapine following a single dose of 5 mg was similar among subjects with varying degrees of renal impairment and subjects with normal renal function.

Hepatic Impairment
In subjects with severe hepatic impairment who were treated with a single dose of asenapine 5 mg, asenapine exposures (on average), were 7-fold higher than the exposures observed in

subjects with normal hepatic function. Thus, asenapine is not recommended in patients with severe hepatic impairment (Child-Pugh C).

DRUG ABUSE AND DEPENDENCE
Abuse
Asenapine has not been systematically studied in animals or humans for its abuse potential or its ability to induce tolerance or physical dependence. Thus, it is not possible to predict the extent to which a CNS-active drug will be misused, diverted and/or abused once it is marketed. Patients should be evaluated carefully for a history of drug abuse, and such patients should be observed carefully for signs that they are misusing or abusing asenapine (e.g., drug-seeking behavior, increases in dose).

CONTRAINDICATIONS
Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed in patients treated with asenapine. Therefore, asenapine is contraindicated in patients with a known hypersensitivity to the product.

WARNINGS AND PRECAUTIONS
Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Asenapine is not approved for the treatment of patients with dementia-related psychosis.

Cerebrovascular Adverse Events, Including Stroke, In Elderly Patients with Dementia-Related Psychosis
In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. Asenapine is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome
A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including asenapine. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia,

diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. It is important to exclude cases where the clinical presentation includes both serious medical illness (e.g. pneumonia, systemic infection) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.
The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.

If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.

Tardive Dyskinesia
A syndrome of potentially irreversible, involuntary, dyskinetic movements can develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause Tardive Dyskinesia (TD) is unknown.

The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.

There is no known treatment for established cases of TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.

Given these considerations, asenapine should be prescribed in a manner that is most likely to minimize the occurrence of TD. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

If signs and symptoms of TD appear in a patient on asenapine, drug discontinuation should be considered. However, some patients may require treatment with asenapine despite the presence of the syndrome.

Metabolic Changes
Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.

Hyperglycemia and Diabetes Mellitus
Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse reactions is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics included in these studies. Because asenapine was not marketed at the time these studies were performed, it is not known if asenapine is associated with this increased risk. Precise risk estimates for hyperglycemia-related adverse events in patients treated with atypical antipsychotics are not available.

Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the antipsychotic drug.

Pooled data from the short-term placebo-controlled schizophrenia and bipolar mania trials are presented in **Table 1. TABLE 1**: **Changes in Fasting Glucose in Adult Patients**

	Schizophrenia (6-weeks)				Bipolar (3-weeks)	
	ASENAPINE					
	Placebo	5 mg twice daily	10 mg twice daily	5 or 10 mg twice daily[§]	Placebo	ASENAPINE 5 or 10 mg twice daily[†]
Mean Change from Baseline in Fasting Glucose at Endpoint						
Change from	-0.2	3.8	1.1	3.2	-0.6	-0.6

Baseline (mg/dL) (N[*])	(232)	(158)	(153)	(377)	(89)	(156)
Proportion of Patients with Shifts from Baseline to Endpoint						
Normal to High <100 to ≥126 mg/dL (n/N[**])	4.1% (7/170)	4.5% (5/111)	4.5% (5/111)	5.0% (13/262)	3.3% (2/61)	2.7% (3/111)
Borderline to High ≥100 and <126 to ≥126 mg/dL (n/N[**])	5.9% (3/51)	6.8% (3/44)	6.3% (2/32)	10.5% (10/95)	0.0% (0/23)	11.4% (4/35)

N[*] = Number of patients who had assessments at both Baseline and Endpoint.
N[**] = Number of patients at risk at Baseline with assessments at both Baseline and Endpoint.
[§] Includes patients treated with flexible dose of asenapine 5 or 10 mg twice daily (N=90).
[†]Asenapine 5 mg or 10 mg twice daily with flexible dosing.

In a 52-week, double-blind, comparator-controlled trial of patients with schizophrenia and schizoaffective disorder, the mean increase from baseline of fasting glucose was 2.4 mg/dL.

Dyslipidemia
Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics. Pooled data from the short-term, placebo-controlled schizophrenia and bipolar mania trials are presented in Table 2.

TABLE 2: Changes in Lipids in Adult Patients

		Schizophrenia (6-weeks)			Bipolar (3-weeks)	
		Asenapine				Asenapine 5 or 10 mg twice daily[†]
	Placebo	5 mg twice daily	10 mg twice daily	5 or 10 mg twice daily[§]	Placebo	
Mean Change from Baseline (mg/dL)						
Total cholesterol(N[*])	-2.2 (351)	-2.4 (258)	3.3 (199)	0.4 (539)	-1.5 (163)	1.1 (322)
LDL (N[*])	0.1 (285)	-0.2 (195)	2.6 (195)	1.3 (465)	1.9 (158)	1.6 (304)
HDL (N[*])	0.5 (290)	0.4 (199)	1.0 (199)	0.5 (480)	0.0 (163)	0.9 (322)
Fasting triglycerides (N[*])	-7.6 (233)	-1.9 (159)	0.1 (154)	3.8 (380)	-17.9 (129)	-3.5 (237)
Proportion of Patients with Shifts from Baseline to Endpoint						
Total cholesterol Normal to High <200 to ≥240 (mg/dL) (n/N[*])	1.3% (3/225)	0.6% (1/161)	2.2% (3/134)	1.7% (6/343)	1.1% (1/95)	2.5% (5/204)
LDL Normal to High <100 to ≥160 (mg/dL) (n/N[*])	1.7% (2/117)	0.0% (0/80)	1.2% (1/86)	1.0% (2/196)	1.9% (1/53)	0.0% (0/141)

HDL Normal to Low mg/dL) (n/N[*])	10.7% (21/196)	13.3% (18/135)	14.7% (20/136)	14.0% (45/322)	7.4% (9/122)	8.7% (21/242)
Fasting triglycerides Normal to High <150 to ≥200 (mg/dL) (n/N[*])	2.4% (4/167)	7.0% (8/115)	8.3% (9/108)	7.7% (20/260)	5.1% (4/78)	7.4% (11/148)

N[*] = Number of subjects who had assessments at both Baseline and Endpoint.
[§] Includes subjects treated with flexible dose of ASENAPINE 5 or 10 mg twice daily (N=90).
[†]ASENAPINE 5 mg or 10 mg twice daily with flexible dosing.

In short-term schizophrenia trials, the proportion of patients with total cholesterol elevations ≥240 mg/dL (at Endpoint) was 8.3% for asenapine-treated patients versus 7% for placebo-treated patients. The proportion of patients with elevations in triglycerides ≥200 mg/dL (at Endpoint) was 13.2% for ASENAPINE-treated patients versus 10.5% for placebo-treated patients. In short-term, placebo-controlled bipolar mania trials, the proportion of patients with total cholesterol elevations ≥240 mg/dL (at Endpoint) was 8.7% for asenapine-treated patients versus 8.6% for placebo-treated patients. The proportion of patients with elevations in triglycerides ≥200 mg/dL (at Endpoint) was 15.2% for asenapine-treated patients versus 11.4% for placebo-treated patients.

In a 52-week, double-blind, comparator-controlled trial of patients with schizophrenia and schizoaffective disorder, the mean decrease from baseline of total cholesterol was 6 mg/dL and the mean decrease from baseline of fasting triglycerides was 9.8 mg/dL.

Weight Gain
Increases in weight have been observed in pre-marketing clinical trials with asenapine. Patients receiving asenapine should receive regular monitoring of weight.

Pooled data on mean changes in body weight and the proportion of subjects meeting a weight gain criterion of ≥7% of body weight from the short-term, placebo-controlled schizophrenia and bipolar mania trials are presented in Table 3.

Table 3: Change in Body Weight in Adult Patients from Baseline

	Asenapine					
	Placebo	5 mg twice daily	10 mg twice daily	5 or 10 mg twice daily [§]	Placebo	Asenapine 5 or 10 mg twice daily[†]
Change from Baseline (kg) (N[*])	0.0 (348)	1.0 (251)	0.9 (200)	1.1 (532)	0.2 (171)	1.3 (336)
Proportion of Patients with a ≥7% Increase in Body Weight						
% with ≥7% increase in body weight	1.6%	4.4%	4.8%	4.9%	0.5%	5.8%

N[*] = Number of subjects who had assessments at both Baseline and Endpoint.

§ Includes subjects treated with flexible dose of asenapine 5 or 10 mg twice daily (N=90).
†asenapine 5 mg or 10 mg twice daily with flexible dosing.

In a 52-week, double-blind, comparator-controlled trial of patients with schizophrenia or schizoaffective disorder, the mean weight gain from baseline was 0.9 kg. The proportion of patients with a ≥7% increase in body weight (at Endpoint) was 14.7%. Table 1 provides the mean weight change from baseline and the proportion of patients with a weight gain of ≥7% categorized by Body Mass Index (BMI) at baseline

Table 4: Weight Change Results Categorized by BMI at Baseline: Comparator-Controlled 52-Week Study in Schizophrenia

	BMI<23 ASENAPINE N=295	BMI-≤27 ASENAPINE N=290	BMI>27 ASENAPINE N=302
Mean change from Baseline (kg)	1.7	1	0
% with ≥7% increase in body weight	22%	13%	9%

Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed in patients treated with asenapine. In several cases, these reactions occurred after the first dose. These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.

Orthostatic Hypotension, Syncope, and Other Hemodynamic Effects
Asenapine may induce orthostatic hypotension and syncope in some patients, especially early in treatment, because of its α1-adrenergic antagonist activity. In short-term schizophrenia trials, syncope was reported in 0.2% (1/572) of patients treated with therapeutic doses (5 mg or 10 mg twice daily) of asenapine, compared to 0.3% (1/378) of patients treated with placebo. In short-term bipolar mania trials, syncope was reported in 0.3% (1/379) of patients treated with therapeutic doses (5 mg or 10 mg twice daily) of asenapine, compared to 0% (0/203) of patients treated with placebo. During pre-marketing clinical trials with asenapine, including long-term trials without comparison to placebo, syncope was reported in 0.6% (11/1953) of patients treated with asenapine.

Four normal volunteers in reported clinical pharmacology studies treated with either intravenous, oral, or sublingual asenapine experienced hypotension, bradycardia, and sinus pauses. These spontaneously resolved in 3 cases, but the fourth subject received external cardiac massage. The risk of this sequence of hypotension, bradycardia, and sinus pause might be greater in nonpsychiatric patients compared to psychiatric patients who are possibly more adapted to certain effects of psychotropic drugs.

Patients should be instructed about nonpharmacologic interventions that help to reduce the occurrence of orthostatic hypotension (e.g., sitting on the edge of the bed for several minutes before attempting to stand in the morning and slowly rising from a seated position). Asenapine should be used with caution in (1) patients with known cardiovascular disease (history of

myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications); and (2) in the elderly. Asenapine should be used cautiously when treating patients who receive treatment with other drugs that can induce hypotension, bradycardia, respiratory or central nervous system depression. Monitoring of orthostatic vital signs should be considered in all such patients, and a dose reduction should be considered if hypotension occurs.

Leukopenia, Neutropenia, and Agranulocytosis
In reported clinical trial and postmarketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents, including asenapine. Agranulocytosis (including fatal cases) has been reported with other agents in the class.

Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (W BC) and history of drug induced leukopenia/neutropenia. Patients with a pre-existing low WBC or a history of drug induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and asenapine should be discontinued at the first sign of decline in WBC in the absence of other causative factors.

Patients with neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count <1000/mm^3) should discontinue asenapine and have their WBC followed until recovery.

QT Prolongation
The effects of asenapine on the QT/QTc interval were evaluated in a dedicated QT study. This reported trial involved asenapine doses of 5 mg, 10 mg, 15 mg, and 20 mg twice daily, and placebo, and was conducted in 151 clinically stable patients with schizophrenia, with electrocardiographic assessments throughout the dosing interval at baseline and steady state. At these doses, asenapine was associated with increases in QTc interval ranging from 2 to 5 msec compared to placebo. No patients treated with asenapine experienced QTc increases ≥60 msec from baseline measurements, nor did any patient experience a QTc of ≥500 msec.

Electrocardiogram (ECG) measurements were taken at various time points during the asenapine clinical trial program (5-mg or 10-mg twice daily doses). Post-baseline QT prolongations exceeding 500 msec were reported at comparable rates for asenapine and placebo in these short-term trials. There were no reports of Torsade de Pointes or any other adverse reactions associated with delayed ventricular repolarization.

The use of asenapine should be avoided in combination with other drugs known to prolong QTc including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and antibiotics (e.g., gatifloxacin, moxifloxacin). Asenapine should also be avoided in patients with a history of cardiac arrhythmias and in other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with

the use of drugs that prolong the QTc interval, including bradycardia; hypokalemia or hypomagnesemia; and presence of congenital prolongation of the QT interval.

Hyperprolactinemia
Like other drugs that antagonize dopamine D2 receptors, asenapine can elevate prolactin levels, and the elevation can persist during chronic administration. Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects. In asenapine clinical trials, the incidences of adverse events related to abnormal prolactin levels were 0.4% versus 0% for placebo.

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent *in vitro*, a factor of potential importance if the prescription of these drugs is considered in a patient with previously-detected breast cancer. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.

Seizures
Seizures were reported in 0% and 0.3% (0/572, 1/379) of patients treated with doses of 5 mg and 10 mg twice daily of asenapine, respectively, compared to 0% (0/503, 0/203) of patients treated with placebo in short-term schizophrenia and bipolar mania trials, respectively. During pre-marketing clinical trials with asenapine, including long-term trials without comparison to placebo, seizures were reported in 0.3% (5/1953) of patients treated with asenapine. As with other antipsychotic drugs, asenapine should be used with caution in patients with a history of seizures or with conditions that potentially lower the seizure threshold, e.g., Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in patients 65 years or older.

Potential for Cognitive and Motor Impairment
Somnolence was reported in patients treated with asenapine. It was usually transient with the highest incidence reported during the first week of treatment. In short-term, fixed-dose, placebo-controlled schizophrenia trials, somnolence was reported in 15% (41/274) of patients on asenapine 5 mg twice daily and in 13% (26/208) of patients on asenapine 10 mg twice daily compared to 7% (26/378) of placebo patients. In short-term, placebo-controlled bipolar mania trials of therapeutic doses (5-10 mg twice daily), somnolence was reported in 24% (90/379) of patients on asenapine compared to 6% (13/203) of placebo patients. During pre-marketing clinical trials with asenapine, including long-term trials without comparison to placebo, somnolence was reported in 18% (358/1953) of patients treated with ASENAPINE. Somnolence (including sedation) led to discontinuation in 0.6% (12/1953) of patients in short-term, placebo-controlled trials.

Patients should be cautioned about performing activities requiring mental alertness, such as operating hazardous machinery or operating a motor vehicle, until they are reasonably certain that asenapine therapy does not affect them adversely.

Body Temperature Regulation
Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. In the short-term placebo-controlled trials for both schizophrenia and acute bipolar disorder, the incidence of adverse reactions suggestive of body temperature increases was low (≤1%) and comparable to placebo. During pre-marketing clinical trials with asenapine, including long-term trials without comparison to placebo, the incidence of adverse reactions suggestive of body temperature increases (pyrexia and feeling hot) was ≤1%. Appropriate care is advised when prescribing asenapine for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.

Suicide
The possibility of a suicide attempt is inherent in psychotic illnesses and bipolar disorder, and close supervision of high-risk patients should accompany drug therapy. Prescriptions for asenapine should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.

Dysphagia
Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Dysphagia was reported in 0.2% and 0% (1/572, 0/379) of patients treated with therapeutic doses (5-10 mg twice daily) of asenapine as compared to 0% (0/378, 0/203) of patients treated with placebo in short-term schizophrenia and bipolar mania trials, respectively. During pre-marketing clinical trials with asenapine, including long-term trials without comparison to placebo, dysphagia was reported in 0.1% (2/1953) of patients treated with asenapine.

Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. asenapine is not indicated for the treatment of dementia-related psychosis, and should not be used in patients at risk for aspiration pneumonia.

Use in Patients with Concomitant Illness
Clinical experience with asenapine in patients with certain concomitant systemic illnesses is limited.

Asenapine has not been evaluated in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from pre-marketing clinical trials. Because of the risk of orthostatic hypotension with asenapine, caution should be observed in cardiac patients.

DRUG ABUSE AND DEPENDENCE
Controlled Substance

Asenapine is not a controlled substance.

Abuse

Asenapine has not been systematically studied in animals or humans for its abuse potential or its ability to induce tolerance or physical dependence. Thus, it is not possible to predict the extent to which a CNS-active drug will be misused, diverted and/or abused once it is marketed. Patients should be evaluated carefully for a history of drug abuse, and such patients should be observed carefully for signs that they are misusing or abusing asenapine (e.g., drug-seeking behavior, increases in dose).

DRUG INTERACTIONS

The risks of using asenapine in combination with other drugs have not been extensively evaluated. Given the primary CNS effects of asenapine, caution should be used when it is taken in combination with other centrally acting drugs or alcohol.

Because of its α1-adrenergic antagonism with potential for inducing hypotension, asenapine may enhance the effects of certain antihypertensive agents.

Potential for Other Drugs to Affect Asenapine

Asenapine is cleared primarily through direct glucuronidation by UGT1A4 and oxidative metabolism by cytochrome P450 isoenzymes (predominantly CYP1A2). The potential effects of inhibitors of several of these enzyme pathways on asenapine clearance were studied.

Table 5: Summary of Effect of Coadministered Drugs on Exposure to Asenapine in Healthy Volunteers

Coadministered drug (Postulated effect on CYP450/UGT)	Dose schedules		Effect on asenapine pharmacokinetics		Recommendation
	Coadministered drug	Asenapine	C_{max}	$AUC_{0-\infty}$	
Fluvoxamine (CYP1A2 inhibitor)	25 mg twice daily for 8 days	5-mg Single Dose	+13%	+29%	Coadminister with caution[*]
Paroxetine (CYP2D6 inhibitor)	20 mg once daily for 9 days	5-mg Single Dose	–13%	–9%	No asenapine dose adjustment required
Imipramine (CYP1A2/2C19/3A4 inhibitor)	75-mg Single Dose	5-mg Single Dose	+17%	+10%	No asenapine dose adjustment required
Cimetidine (CYP3A4/2D6/1A2 inhibitor)	800 mg twice daily for 8 days	5-mg Single Dose	–13%	+1%	No asenapine dose adjustment required
Carbamazepine (CYP3A4 inducer)	400 mg twice daily for 15 days	5-mg Single Dose	–16%	–16%	No asenapine dose adjustment required

Valproate (UGT1A4 inhibitor)	500 mg twice daily for 9 days	5-mg Single Dose	2%	−1%	No asenapine dose adjustment required

* The full therapeutic dose of fluvoxamine would be expected to cause a greater increase in asenapine plasma concentrations. AUC: Area under the curve.

A population pharmacokinetic analysis indicated that the concomitant administration of lithium had no effect on the pharmacokinetics of asenapine.

Potential for Asenapine to Affect Other Drugs
Coadministration with CYP2D6 Substrates: In vitro studies indicate that asenapine weakly inhibits CYP2D6.

Following coadministration of dextromethorphan and asenapine in healthy subjects, the ratio of dextrorphan/dextromethorphan (DX/DM) as a marker of CYP2D6 activity was measured. Indicative of CYP2D6 inhibition, treatment with asenapine 5 mg twice daily decreased the DX/DM ratio to 0.43. In the same study, treatment with paroxetine 20 mg daily decreased the DX/DM ratio to 0.032. In a separate study, coadministration of a single 75-mg dose of imipramine with a single 5-mg dose of asenapine did not affect the plasma concentrations of the metabolite desipramine (a CYP2D6 substrate). Thus, *in vivo*, asenapine appears to be at most a weak inhibitor of CYP2D6. Coadministration of a single 20-mg dose of paroxetine (a CYP2D6 substrate and inhibitor) during treatment with 5 mg asenapine twice daily in 15 healthy male subjects resulted in an almost 2-fold increase in paroxetine exposure. Asenapine may enhance the inhibitory effects of paroxetine on its own metabolism.

Asenapine should be coadministered cautiously with drugs that are both substrates and inhibitors for CYP2D6.

Valproic acid and lithium pre-dose serum concentrations collected from an adjunctive therapy study were comparable between asenapine treated patients and placebo treated patients indicating a lack of effect of asenapine on valproic and lithium plasma levels.

UNDESIRABLE EFFECTS

The following adverse reactions are discussed in more detail in other sections of the labeling:

- Use in Elderly Patients with Dementia-Related Psychosis
- Neuroleptic Malignant Syndrome
- Tardive Dyskinesia
- Metabolic Changes
- Hypersensitivity Reactions
- Application site reactions including oral ulcers, blisters, peeling/sloughing and inflammation
- Orthostatic Hypotension, Syncope, and other Hemodynamic Effects

- Leukopenia, Neutropenia, and Agranulocytosis
- QT Interval Prolongation
- Hyperprolactinemia
- Seizures
- Potential for Cognitive and Motor Impairment
- Body Temperature Regulation
- Suicide
- Dysphagia
- Use in Patients with Concomitant Illness

The most common adverse reactions (≥5% and at least twice the rate of placebo) reported with acute treatment in schizophrenia were akathisia, oral hypoesthesia, and somnolence. The safety profile of ASENAPINE in the maintenance treatment of schizophrenia was similar to that seen with acute treatment.

The most common adverse reactions (≥5% and at least twice the rate of placebo) reported with acute monotherapy treatment of manic or mixed episodes associated with bipolar I disorder were somnolence, dizziness, extrapyramidal symptoms other than akathisia, and weight increased and during the adjunctive therapy trial in bipolar disorder were somnolence and oral hypoesthesia.

The information below is derived from a clinical trial database for asenapine consisting of over 4565 patients and/or normal subjects exposed to one or more sublingual doses of asenapine. A total of 1314 asenapine-treated patients were treated for at least 24 weeks and 785 asenapine-treated patients had at least 52 weeks of exposure at therapeutic doses.

The stated frequencies of adverse reactions represent the proportion of individuals who experienced a treatment-emergent adverse event of the type listed. A reaction was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.

The figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatment, uses, and investigators. The cited figures, however, do provide the prescriber with some basis for estimating the relative contribution of drug and nondrug factors to the adverse reaction incidence in the population studied.

Clinical Studies Experience
Adult Patients with Schizophrenia: The following findings are based on the short-term placebo-controlled pre-marketing trials for schizophrenia (a pool of three 6-week fixed-dose trials and one 6-week flexible-dose trial) in which sublingual asenapine was administered in doses ranging from 5 to 10 mg twice daily.

Adverse Reactions Associated with Discontinuation of Treatment: A total of 9% of asenapine-treated subjects and 10% of placebo subjects discontinued due to adverse reactions. There were no drug-related adverse reactions associated with discontinuation in subjects treated with asenapine at the rate of at least 1% and at least twice the placebo rate.

Adverse Reactions Occurring at an Incidence of 2% or More in asenapine-Treated Schizophrenic Patients: Adverse reactions associated with the use of asenapine (incidence of 2% or greater, rounded to the nearest percent, and asenapine incidence greater than placebo) that occurred during acute therapy (up to 6-weeks in patients with schizophrenia) are shown in **Table 6**.

Table 6: Adverse Reactions Reported in 2% or More of Subjects in One of the Asenapine Dose Groups and Which Occurred at Greater Incidence than in the Placebo Group in 6-Week Schizophrenia Trials

System Organ Class/ Preferred Term	Placebo N=378	Asenapine 5 mg twice daily N=274	Asenapine 10 mg twice daily N=208	All Asenapine[§] 5 mg or 10 mg twice daily N=572
Gastrointestinal disorders				
Constipation	6%	7%	4%	5%
Dry mouth	1%	3%	1%	2%
Oral hypoesthesia	1%	6%	7%	5%
Salivary hypersecretion	0%	<1%	4%	2%
Stomach discomfort	1%	<1%	3%	2%
Vomiting	5%	4%	7%	5%
General disorders				
Fatigue	3%	4%	3%	3%
Irritability	<1%	2%	1%	2%
Investigations				
Weight increased	<1%	2%	2%	3%
Metabolism disorders				
Increased appetite	<1%	3%	0%	2%
Nervous system disorders				
Akathisia[*]	3%	4%	11%	6%
Dizziness	4%	7%	3%	5%
Extrapyramidal symptoms (excluding akathisia)[†]	7%	9%	12%	10%
Somnolence[‡]	7%	15%	13%	13%
Psychiatric disorders				
Insomnia	13%	16%	15%	15%
Vascular disorders				
Hypertension	2%	2%	3%	2%

[*] Akathisia includes: akathisia and hyperkinesia.

[†]Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).
[‡] Somnolence includes the following events: somnolence, sedation, and hypersomnia.
§ Also includes the Flexible-dose trial (N=90)

Dose-Related Adverse Reactions: Of all the adverse reactions, the only apparent dose-related adverse reaction was akathisia.

Monotherapy in Adult Patients with Bipolar Mania: The following findings are based on the short-term placebo-controlled trials for bipolar mania (a pool of two 3-week flexible-dose trials) in which sublingual asenapine was administered in doses of 5 mg or 10 mg twice daily.

Adverse Reactions Associated with Discontinuation of Treatment: Approximately 10% (38/379) of asenapine-treated patients in short-term, placebo-controlled trials discontinued treatment due to an adverse reaction, compared with about 6% (12/203) on placebo. The most common adverse reactions associated with discontinuation in subjects treated with asenapine (rates at least 1% and at least twice the placebo rate) were anxiety (1.1%) and oral hypoesthesia (1.1%) compared to placebo (0%).

Adverse Reactions Occurring at an Incidence of 2% or More Among asenapine-Treated (Monotherapy) Bipolar Patients: Adverse reactions associated with the use of ASENAPINE (incidence of 2% or greater, rounded to the nearest percent, and asenapine incidence greater than placebo) that occurred during acute monotherapy (up to 3-weeks in patients with bipolar mania) are shown in Table 6.

Table 7: Adverse Reactions Reported in 2% or More of Subjects in One of the asenapine Dose Groups and Which Occurred at Greater Incidence than in the Placebo Group in 3-Week Bipolar Mania Trials

System Organ Class/Preferred Term	Placebo N=203	Asenapine 5 mg or 10 mg twice daily* N=379
Gastrointestinal disorders		
Dry mouth	1%	3%
Dyspepsia	2%	4%
Oral hypoesthesia	<1%	4%
Toothache	2%	3%
General disorders		
Fatigue	2%	4%
Investigations		
Weight increased	<1%	5%
Metabolism disorders		
Increased appetite	1%	4%
Musculoskeletal and connective tissue disorders		
Arthralgia	1%	3%
Pain in extremity	<1%	2%

Nervous system disorders		
Akathisia	2%	4%
Dizziness	3%	11%
Dysgeusia	<1%	3%
Headache	11%	12%
Other extrapyramidal symptoms (excluding akathisia)[†]	2%	7%
Somnolence[‡]	6%	24%
Psychiatric disorders		
Anxiety	2%	4%
Depression	1%	2%
Insomnia	5%	6%

[*] Asenapine 5 mg to 10 mg twice daily with flexible dosing.
[†] Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).
[‡] Somnolence includes the following events: somnolence, sedation, and hypersomnia.

Adjunctive Therapy in Adult Patients with Bipolar Mania: The following findings are based on a 12 week placebo-controlled trial (with a 3 week efficacy endpoint) in adult patients with bipolar mania in which sublingual asenapine was administered in doses of 5 mg or 10 mg twice daily as adjunctive therapy with lithium or valproate.

Adverse Reactions Associated with Discontinuation of Treatment: Approximately 16% (25/158) of asenapine-treated patients discontinued treatment due to an adverse reaction, compared with about 11% (18/166) on placebo. The most common adverse reactions associated with discontinuation in subjects treated with asenapine (rates at least 1% and at least twice the placebo rate) were depression (2.5%), suicidal ideation (2.5%), bipolar 1 disorder (1.9%), insomnia (1.9%) and depressive symptoms (1.3%).

Adverse Reactions Occurring at an Incidence of 2% or More Among asenapine-Treated (Adjunctive) Bipolar Patients: Adverse reactions associated with the use of asenapine (incidence of 2% or greater, rounded to the nearest percent, and asenapine incidence greater than placebo) that occurred during acute adjunctive therapy at 3 weeks, a time when most of the patients were still participating in the trial, are shown in **Table 7**.

Table 8: Adverse Reactions Reported in 2% or More among Asenapine-Treated (Adjunctive) Bipolar Mania Patients and Which Occurred at Greater Incidence Than in the Placebo Group at 3 Weeks

System Organ Class/Preferred Term	Placebo N=166	Asenapine 5 mg or 10 mg twice daily[*] N=158
Gastrointestinal disorders		
Dyspepsia	2%	3%
Oral hypoesthesia	0%	5%
General disorders		

Fatigue	2%	4%
Edema peripheral	<1%	3%
Investigations		
Weight increased	0%	3%
Nervous system disorders		
Dizziness	2%	4%
Other extrapyramidal symptoms (excluding akathisia)[†]	5%	6%
Somnolence[‡]	10%	22%
Psychiatric disorders		
Insomnia	8%	10%
Vascular disorders		
Hypertension	<1%	3%

[*] Asenapine 5 mg to 10 mg twice daily with flexible dosing.
[†] Extrapyramidal symptoms included: dystonia, parkinsonism, oculogyration, and tremor (excluding akathisia).
[‡] Somnolence includes the following events: somnolence and sedation.

Dystonia: *Antipsychotic Class Effect:* Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

Extrapyramidal Symptoms: In the short-term, placebo-controlled schizophrenia and bipolar mania trials, data was objectively collected on the Simpson Angus Rating Scale for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (for akathisia) and the Assessments of Involuntary Movement Scales (for dyskinesias). The mean change from baseline for the all-asenapine 5 mg or 10 mg twice daily treated group was comparable to placebo in each of the rating scale scores.

In the short-term, placebo-controlled schizophrenia trials, the incidence of reported EPS-related events, excluding events related to akathisia, for asenapine-treated patients was 10% versus 7% for placebo; and the incidence of akathisiarelated events for asenapine-treated patients was 6% versus 3% for placebo. In short-term placebo-controlled bipolar mania trials, the incidence of EPS-related events, excluding events related to akathisia, for asenapine-treated patients was 7% versus 2% for placebo; and the incidence of akathisia-related events for asenapine-treated patients was 4% versus 2% for placebo.

Other Findings: Oral hypoesthesia and/or oral paraesthesia may occur directly after administration of asenapine and usually resolves within 1 hour.

Laboratory Test Abnormalities:

<u>Transaminases:</u> Transient elevations in serum transaminases (primarily ALT) in the short-term schizophrenia and bipolar mania trials were more common in treated patients but mean changes were not clinically relevant. In short-term, placebo-controlled schizophrenia trials, the mean increase in transaminase levels for asenapine-treated patients was 1.6 units/L compared to a decrease of 0.4 units/L for placebo-treated patients. The proportion of patients with transaminase elevations ≥3 times ULN (at Endpoint) was 0.9% for asenapine-treated patients versus 1.3% for placebo-treated patients. In short-term, placebo-controlled bipolar mania trials, the mean increase in transaminase levels for asenapine-treated patients was 8.9 units/L compared to a decrease of 4.9 units/L in placebo-treated patients. The proportion of patients with transaminase elevations ≥3 times upper limit of normal (ULN) (at Endpoint) was 2.5% for asenapine-treated patients versus 0.6% for placebo-treated patients. No cases of more severe liver injury were seen.

In a 52-week, double-blind, comparator-controlled trial of patients with schizophrenia and schizoaffective disorder, the mean increase from baseline of ALT was 1.7 units/L.

<u>Prolactin:</u> The effects on prolactin levels in the short-term schizophrenia and bipolar mania trials revealed no clinically relevant mean changes in baseline. In short-term, placebo-controlled schizophrenia trials, the mean decreases in prolactin levels were 6.5 ng/mL for asenapine-treated patients compared to 10.7 ng/mL for placebo-treated patients. The proportion of patients with prolactin elevations ≥4 times ULN (at Endpoint) were 2.6% for asenapine-treated patients versus 0.6% for placebo-treated patients. In short-term, placebo-controlled bipolar mania trials, the mean increase in prolactin levels was 4.9 ng/mL for asenapine-treated patients compared to a decrease of 0.2 ng/mL for placebo-treated patients. The proportion of patients with prolactin elevations ≥4 times ULN (at Endpoint) were 2.3% for asenapine-treated patients versus 0.7% for placebo-treated patients.

In a long-term (52-week), double-blind, comparator-controlled trial of patients with schizophrenia and schizoaffective disorder, the mean decrease in prolactin from baseline for asenapine-treated patients was 26.9 ng/mL.

<u>Creatine Kinase (CK):</u> The proportion of patients with CK elevations >3 times ULN at any time were 6.4% and 11.1% for patients treated with asenapine 5 mg bid and 10 mg bid, respectively, as compared to 6.7% for placebo-treated patients in short-term, fixed-dose trials in schizophrenia and bipolar mania. The clinical relevance of this finding is unknown.

Other Adverse Reactions Observed During the Premarketing Evaluation of Asenapine: Following is a list of MedDRA terms that reflect adverse reactions reported by patients treated with sublingual asenapine at multiple doses of ≥5 mg twice daily during any phase of a trial within the database of adult patients. The reactions listed are those that could be of clinical importance, as well as reactions that are plausibly drug-related on pharmacologic or other grounds. Reactions already listed in other parts of Adverse Reactions (6), or those considered in Warnings and Precautions (5) or Overdo sage (10) are not included. Although the reactions reported occurred during treatment with asenapine, they were not necessarily caused by it. Reactions are further categorized by MedDRA system organ class and listed in order of decreasing frequency according to the following definitions: those occurring in at least 1/100 patients (only those not already listed in the tabulated results from placebo-controlled trials

appear in this listing); those occurring in 1/100 to 1/1000 patients; and those occurring in fewer than 1/1000 patients.

Blood and lymphatic disorders: <1/1000 patients: thrombocytopenia; ≥1/1000 patients and <1/100 patients: anemia

Cardiac disorders: ≥1/1000 patients and <1/100 patients: tachycardia, temporary bundle branch block

Eye disorders: ≥1/1000 patients and <1/100 patients: accommodation disorder

Gastrointestinal disorders: ≥1/1000 patients and <1/100 patients: oral paraesthesia, glossodynia, swollen tongue

General disorders: <1/1000 patients: idiosyncratic drug reaction

Investigations: ≥1/1000 patients and <1/100 patients: hyponatremia

Nervous system disorders: ≥1/1000 patients and <1/100 patients: dysarthria

Postmarketing Experience
The following adverse reactions have been identified during post-approval use of asenapine. Application site reactions, primarily in the sublingual area, have been reported. These application site reactions included oral ulcers, blisters, peeling/sloughing, and inflammation. In many cases, the occurrence of these application site reactions led to discontinuation of therapy.

OVERDOSE
Human Experience: In pre-marketing clinical studies involving more than 3350 patients and/or healthy subjects, accidental or intentional acute overdosage of asenapine was identified in 3 patients. Among these few reported cases of overdose, the highest estimated ingestion of asenapine was 400 mg. Reported adverse reactions at the highest dosage included agitation and confusion.

Management of Overdosage: There is no specific antidote to asenapine. The possibility of multiple drug involvement should be considered. An electrocardiogram should be obtained and management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms.

Hypotension and circulatory collapse should be treated with appropriate measures, such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen hypotension in the setting of asenapine-induced alpha blockade). In case of severe extrapyramidal symptoms, anticholinergic medication should be administered. Close medical supervision and monitoring should continue until the patient recovers.

PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES

Mechanism of Action
The mechanism of action of asenapine, as with other drugs having efficacy in schizophrenia and bipolar disorder, is unknown. It has been suggested that the efficacy of asenapine in schizophrenia is mediated through a combination of antagonist activity at D_2 and $5\text{-}HT_{2A}$ receptors.

Pharmacodynamics
Asenapine exhibits high affinity for serotonin $5\text{-}HT_{1A}$, $5\text{-}HT_{1B}$, $5\text{-}HT_{2A}$, $5\text{-}HT_{2B}$, $5\text{-}HT_{2C}$, $5\text{-}HT_{5A}$, $5\text{-}HT_6$, and $5\text{-}HT_7$ receptors (Ki values of 2.5, 2.7, 0.07, 0.18, 0.03, 1.6, 0.25, and 0.11nM, respectively), dopamine D_{2A}, D_{2B}, D_3, D_4, and D_1 receptors (Ki values of 1.3, 1.4, 0.42, 1.1, and 1.4 nM, respectively), α_{1A}, α_{2A}, α_{2B}, and α_{2C} -adrenergic receptors (Ki values of 1.2, 1.2, 0.33 and 1.2 nM, respectively), and histamine H_1 receptors (Ki value 1.0 nM), and moderate affinity for H_2 receptors (Ki value of 6.2 nM). In *in vitro* assays asenapine acts as an antagonist at these receptors. Asenapine has no appreciable affinity for muscarinic cholinergic receptors (e.g., Ki value of 8128 nM for M_1).

Pharmacokinetics
Following a single 5-mg dose of asenapine, the mean C_{max} was approximately 4 ng/mL and was observed at a mean t_{max} of 1 hour. Elimination of asenapine is primarily through direct glucuronidation by UGT1A4 and oxidative metabolism by cytochrome P450 isoenzymes (predominantly CYP1A2). Following an initial more rapid distribution phase, the mean terminal half-life is approximately 24 hrs. With multiple-dose twice-daily dosing, steady-state is attained within 3 days. Overall, steady-state asenapine pharmacokinetics are similar to single-dose pharmacokinetics.

Absorption: Following sublingual administration, asenapine is rapidly absorbed with peak plasma concentrations occurring within 0.5 to 1.5 hours. The absolute bioavailability of sublingual asenapine at 5 mg is 35%. Increasing the dose from 5 mg to 10 mg twice daily (a two-fold increase) results in less than linear (1.7 times) increases in both the extent of exposure and maximum concentration. The absolute bioavailability of asenapine when swallowed is low (<2% with an oral tablet formulation).

The intake of water several (2 or 5) minutes after asenapine administration resulted in decreased asenapine exposure. Therefore, eating and drinking should be avoided for 10 minutes after administration.

Distribution: Asenapine is rapidly distributed and has a large volume of distribution (approximately 20 -25 L/kg), indicating extensive extravascular distribution. Asenapine is highly bound (95%) to plasma proteins, including albumin and α1-acid glycoprotein.

Metabolism and Elimination: Direct glucuronidation by UGT1A4 and oxidative metabolism by cytochrome P450 isoenzymes (predominantly CYP1A2) are the primary metabolic pathways for asenapine.

Asenapine is a high clearance drug with a clearance after intravenous administration of 52 L/h. In this circumstance, hepatic clearance is influenced primarily by changes in liver blood flow

rather than by changes in the intrinsic clearance, i.e., the metabolizing enzymatic activity. Following an initial more rapid distribution phase, the terminal half life of asenapine is approximately 24 hours. Steady-state concentrations of asenapine are reached within 3 days of twice daily dosing.

After administration of a single dose of [^{14}C]-labeled asenapine, about 90% of the dose was recovered; approximately 50% was recovered in urine, and 40% recovered in feces. About 50% of the circulating species in plasma have been identified. The predominant species was asenapine N+-glucuronide; others included N-desmethylasenapine, N-desmethylasenapine N-carbamoyl glucuronide, and unchanged asenapine in smaller amounts. Asenapine activity is primarily due to the parent drug.

In vitro studies indicate that asenapine is a substrate for UGT1A4, CYP1A2 and to a lesser extent CYP3A4 and CYP2D6. Asenapine is a weak inhibitor of CYP2D6. Asenapine does not cause induction of CYP1A2 or CYP3A4 activities in cultured human hepatocytes. Coadministration of asenapine with known inhibitors, inducers or substrates of these metabolic pathways has been studied in a number of drug-drug interaction studies.

Smoking: A population pharmacokinetic analysis indicated that smoking, which induces CYP1A2, had no effect on the clearance of asenapine in smokers. In a crossover study in which 24 healthy male subjects (who were smokers) were administered a single 5-mg sublingual dose, concomitant smoking had no effect on the pharmacokinetics of asenapine.

Food: A crossover study in 26 healthy male subjects was performed to evaluate the effect of food on the pharmacokinetics of a single 5-mg dose of asenapine. Consumption of food immediately prior to sublingual administration decreased asenapine exposure by 20%; consumption of food 4 hours after sublingual administration decreased asenapine exposure by about 10%. These effects are probably due to increased hepatic blood flow.

In clinical trials establishing the efficacy and safety of asenapine, patients were instructed to avoid eating for 10 minutes following sublingual dosing. There were no other restrictions with regard to the timing of meals in these trials.

Water: In clinical trials establishing the efficacy and safety of asenapine, patients were instructed to avoid drinking for 10 minutes following sublingual dosing. The effect of water administration following 10-mg sublingual asenapine dosing was studied at different time points of 2, 5, 10, and 30 minutes in 15 healthy male subjects. The exposure of asenapine following administration of water 10 minutes after sublingual dosing was equivalent to that when water was administered 30 minutes after dosing. Reduced exposure to asenapine was observed following water administration at 2 minutes (19% decrease) and 5 minutes (10% decrease).

Special Populations:
Hepatic Impairment: The effect of decreased hepatic function on the pharmacokinetics of asenapine, administered as a single 5-mg sublingual dose, was studied in 30 subjects (8 each in those with normal hepatic function and Child-Pugh A and B groups, and 6 in the Child-Pugh C group). In subjects with mild or moderate hepatic impairment (Child-Pugh A or B), asenapine

exposure was 12% higher than that in subjects with normal hepatic function, indicating that dosage adjustment is not required for these subjects. In subjects with severe hepatic impairment, asenapine exposures were on average 7 times higher than the exposures of those in subjects with normal hepatic function. Thus, asenapine is not recommended in patients with severe hepatic impairment (Child-Pugh C).

Renal Impairment: The effect of decreased renal function on the pharmacokinetics of asenapine was studied in subjects with mildly (creatinine clearance (CrCl) 51 to 80 mL/min; N=8), moderately (CrCl 30 to 50 mL/min; N=8), and severely (CrCl less than 30 mL/min but not on dialysis; N=8) impaired renal function and compared to normal subjects (CrCl greater than 80 mL/min; N=8). The exposure of asenapine following a single dose of 5 mg was similar among subjects with varying degrees of renal impairment and subjects with normal renal function. Dosage adjustment based upon degree of renal impairment is not required. The effect of renal function on the excretion of other metabolites and the effect of dialysis on the pharmacokinetics of asenapine has not been studied.

Geriatric Patients: In elderly patients (N=96) with psychosis (65-85 years of age), asenapine exposure (AUC) was on average 40% higher compared to younger adult patients. No dosage adjustment is necessary. In a population pharmacokinetic analysis, a decrease in clearance with increasing age was observed, implying a 30% higher exposure in elderly as compared to adult patients.

Gender: The potential difference in asenapine pharmacokinetics between males and females was not studied in a dedicated trial. In a population pharmacokinetic analysis, no significant differences between genders were observed.

Race: In a population pharmacokinetic analysis, no effect of race on asenapine concentrations was observed. In a dedicated study, the pharmacokinetics of asenapine were similar in Caucasian and Japanese subjects.

EPIRY DATE
Do not use later than date of expiry.

PAKAGING INFORMATION
WELENUF 5 and WELENUF 10 are available as blister pack of 10 tablets.

STORAGE AND HANDLING INSTRUCTIONS
Store below 25°C. Protect from light and moisture. Keep out of reach of children

Method for Administering Tablet :
If the patient is unable to take the tablet as described below, the treatment may not be effective and Welenuf is not advised for such patients.

Instructions for use:
• When taken in combination with other medicines, Welenuf should be taken last
• Do not remove a tablet from the strip until ready to take it

- Use dry hands while handling the tablet
- Gently remove the tablet from strip. Do not crush the tablet
- To ensure optimal absorption, place the tablet under the tongue (see picture below) close the mouth and wait until it dissolves completely

- Do not swallow or chew the tablet
- Do not swallow the saliva
- Do not eat, drink or smoke while the tablet is dissolving
- Do not eat, drink or rinse for 10 minutes after taking the tablet
- Less or altered sensation may occur directly after administration and usually resolves within 1 hour
- Do not cut or push tablets through tablets pack.

MARKETED BY

TORRENT PHARMACEUTICALS LTD.
Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

WELE/NOV 2014/Ver 01